Posted by Michael Wonder on 04 Jul 2016
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients
4 July 2016 - New indication allows Kyprolis to be used in combination with dexamethasone alone for appropriate patients.
Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
The extended indication marks the second approval for Kyprolis by the EC in less than a year.
